Tabrecta (capmatinib) [product monograph]. HC.

Regulatory approval published by the Health Canada.

Citation

Novartis Pharmaceuticals Canada Inc. Tabrecta (capmatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071417.PDF. Revised June 2023. Accessed June 2025.

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
TABRECTA (capmatinib tablets) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. 2

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) MET Exon 14 (Splice Site) Non-Small Cell Lung Cancer Capmatinib
Sensitivity (+) MET Exon 14 (Deletion) Non-Small Cell Lung Cancer Capmatinib